MDxHealth reports $27.4M revenue in Q1 2026, focusing on prostate cancer diagnostics after exiting the Resolve UTI business. Future growth projected at 20-26%.

Key Takeaways

• Q1 2026 revenue totaled $27.4 million, with core prostate cancer operations generating $23.9 million, marking an 11% increase year-over-year.
• The company reported a pro forma gross margin of 62.9% for the quarter, down from 68% in Q1 2025, primarily due to a change in the tissue versus liquid mix.
• MDxHealth's net loss for Q1 2026 was $8.9 million, with a pro forma net loss of $9.4 million, reflecting manageable operational challenges within the core business.
• The company established a revised revenue guidance for 2026, anticipating core cancer business revenue of $110 to $115 million, projecting a 20-26% growth rate year-over-year.
• An important strategic pivot involved exiting the Resolve UTI business, allowing greater focus on the prostate cancer diagnostics market.

Financial Performance

In the first quarter of 2026, MDxHealth SA reported a total revenue of $27.4 million. However, when considering only its ongoing prostate cancer operations, the revenue reached $23.9 million, which signifies an 11% increase from the same period last year. This growth reflects the effective integration of the sales team and a concentrated focus on precision diagnostics related to prostate cancer.

The statutory gross profit for the quarter was $16.6 million, yielding a gross margin of 60.5%. In comparison, the pro forma gross profit, excluding the discontinued Resolve business, was $15 million, translating to a gross margin of 62.9%, a decline from 68% in Q1 2025. The decrease was attributed to the evolving product mix between tissue and liquid biopsies.

Despite the challenges, the company’s operating expenses for the quarter totaled $23.9 million, leading to an operating loss of $7.3 million. When adjusted for the Resolve business, the pro forma operating loss was $7.9 million, a decline from a pro forma loss of $4.7 million in the prior year. The net loss stood at $8.9 million, primarily driven by integration costs associated with the acquisition of the ExoDx business.

Strategic Initiatives

MDxHealth's management emphasized a significant strategic shift during the call, notably the decision to discontinue the Resolve UTI offering. This decision was influenced by the unpredictable reimbursement landscape and a recent policy reversal from the company’s Medicare Administrator, Novitas, leading to potential recoupments of up to $10.4 million in historical claims.

Michael McGarrity, CEO, highlighted that exiting this business line would allow the company to concentrate entirely on its prostate cancer diagnostics portfolio, including the Confirm GPS and ExoDx tests. This strategic refocus aims to enhance operational efficiency and sales effectiveness across the organization. The transition of Resolve customers to the ExoDx platform was completed within the first quarter, further aligning the sales force with the company’s core offerings.

In addition, MDxHealth is leveraging artificial intelligence (AI) to enhance its diagnostic capabilities. The company initiated an AI strategic initiative aimed at developing a robust data platform utilizing unique biopsy tissue specimens. Collaborations with prestigious institutions, like the University of Oxford, and partnerships with digital innovation firms are expected to drive advancements in diagnostic accuracy and patient care.

Future Outlook

Looking ahead, MDxHealth has set an optimistic revenue guidance for its core cancer business, forecasting revenues between $110 million and $115 million for 2026. This guidance translates to a growth rate of 20-26% compared to the previous year, reflecting the company’s confidence in its streamlined operations and market position in the urology sector.

Management shared their commitment to quality and customer satisfaction, asserting that their focus on the prostate cancer diagnostics will solidify their reputation in the market. They anticipate that the operational reset, following the exit from the Resolve business, will ultimately yield sustainable growth and profitability.

The company also reassured investors about its solid financial position, with cash and cash equivalents amounting to $43.2 million as of March 31, 2026. This financial cushion is expected to support ongoing operations and the integration of new initiatives.

Overall, MDxHealth’s strategic exit from the Resolve business, combined with its commitment to enhancing its core offerings and leveraging AI, positions the company favorably for future growth. The management’s focus on operational discipline and transparency remains critical as they navigate the healthcare landscape.

In conclusion, while MDxHealth faces challenges due to external market pressures, its strategic initiatives and robust growth trajectory in the prostate cancer diagnostics segment provide a positive outlook for stakeholders and investors alike.

This analysis is based on public earnings call materials and is not investment advice.